Evidence map›Paper›PMID 38824910›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2025

Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS.

Anne L Peters, Raffaella Buzzetti, Clare J Lee, Imre Pavo, Minzhi Liu, Chrisanthi A Karanikas, Jim S Paik

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anne L PetersUniversity of Southern California Clinical Diabetes Program, Keck School of Medicine of the University of Southern California, Los Angeles, Los Angeles, CA 90033, USA.
Raffaella BuzzettiDepartment of Experimental Medicine, Sapienza University of Rome, Rome 00160, Italy.
Clare J LeeEli Lilly and Company, Indianapolis, IN 46285, USA.ORCID 0000-0002-0824-0207
Imre PavoEli Lilly and Company, Indianapolis, IN 46285, USA.
Minzhi LiuTigermed-BCM Inc, Somerset, NJ 08873, USA.
Chrisanthi A KaranikasEli Lilly and Company, Indianapolis, IN 46285, USA.
Jim S PaikEli Lilly and Company, Indianapolis, IN 46285, USA.

Funding

New York Regional Center for Diabetes Translation Research - Translational Intervention Methodology CoreP30DK111022 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY GONZALEZ · 2016 to 2026
$7.8M
Eli Lilly and CompanyNIDDK NIH HHS P30 DK111022
6 · The paper itself

Abstract

contextPeople with clinically diagnosed type 2 diabetes (T2D) but positive antiglutamic acid decarboxylase autoantibodies (GADA), referred to here as latent autoimmune diabetes in adults (LADA), may experience more rapid glycemic deterioration than those with T2D and may benefit from effective diabetes treatment with additional metabolic benefits.

objectiveThis work aimed to assess glycated hemoglobin A1c (HbA1c) and body weight (BW) changes associated with tirzepatide in GADA-positive vs GADA-negative participants with a clinical T2D diagnosis.

methodsPost hoc analyses based on pooled data from SURPASS 2-5, using mixed-model repeated measures from the efficacy analysis set, adjusting for study and baseline covariates including age, sex, baseline values, body mass index (BMI), and GADA status, were conducted on 3791 individuals. Intervention included tirzepatide (5, 10, 15 mg). Main outcome measure included change from baseline in HbA1c at weeks 40 (SURPASS-2, -3, -5) and 42 (SURPASS-4) by GADA status.

resultsIn participants with confirmed GADA status, 3671 (96.8%) were GADA negative and 120 (3.2%) were GADA positive (76 [63.3%] with low and 44 [36.7%] with high GADA levels). Baseline characteristics were similar between groups, except for slightly lower BMI in GADA-positive vs GADA-negative participants (mean [SD] BMI 32.2 [6.1] vs 33.6 [6.3]). At week 40/42, both groups achieved robust reductions in HbA1c (-2.11% vs -2.32%) and BW (-9.2 kg vs -9.6 kg) (P < .001, both groups). HbA1c reductions were greater in GADA-negative participants (estimated difference [95% CI]: 0.21% [0.03, 0.39]; P = .024) and BW reductions did not differ between groups (0.38 kg [-0.99, 1.75]; P = .588).

conclusionIn this post hoc analysis, tirzepatide was associated with substantial reductions in HbA1c and BW irrespective of GADA status in adults diagnosed with T2D, suggesting that tirzepatide may improve glycemic control in individuals with LADA.

Indexed as

AutoantibodiesBody WeightDiabetes Mellitus, Type 2Glutamate DecarboxylaseGlycated HemoglobinHypoglycemic AgentsLatent Autoimmune Diabetes in AdultsAdultAgedBlood GlucoseBody Mass IndexFemaleHumansMaleMiddle AgedTirzepatideAutoantibodiesBlood GlucoseGlutamate DecarboxylaseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsTirzepatideGADALADASURPASStirzepatidetype 2 diabetes

Identifiers

PMID38824910
PMCPMC11913103

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.